GABA Transporter-2在克罗恩病中的表达及意义的临床研究

目的　探讨GABA Transporter-2（GAT-2）在克罗恩病（CD）肠组织中的表达及其与临床病理特征的关系。方法　选取2010年3月至2021年3月期间于扬州大学附属医院就诊的56例CD患者作为观察组，男性27例，女性29例，年龄为（32.30±9.40）岁；选择同期健康体检者68例作为对照组，男性32例，女性36例，年龄为（34.76±7.70）岁。两组均经肠镜检查后送病理诊断，采用免疫组化染色法测定GAT-2在CD患者肠黏膜组织与健康体检者肠黏膜组织中的表达并比较；分析CD患者中GAT-2表达与炎症状态的关系及其与临床病例参数间的关系。运用SPSS 25.0软件进行统计学分析，符合正态分布的计量资料行t检验，计数资料行χ²检验。结果　观察组肠黏膜组织中GAT-2阳性表达率显著高于对照组［83.93%（47/56）比7.35%（5/68）］，差异有统计学意义（χ²=73.954，P<0.05）；CD患者中GAT-2在重度活动期的表达评分高于中度活动期、轻度活动期和缓解期，差异均有统计学意义（均P<0.05），GAT-2表达评分与简化CD疾病活动指数（CDAI）评分呈正相关性（P<0.05）；C反应蛋白（CRP）水平升高、红细胞沉降率（ESR）升高、有肛周病变的CD患者GAT-2表达阳性率高于CRP正常、ESR正常、无肛周病变的CD患者，差异均有统计学意义（均P<0.05）。结论　GAT-2在CD患者肠黏膜组织中呈高表达，主要表达在间质淋巴细胞胞浆中，且其表达评分与CD临床分期具有相关性，可作为临床诊断的辅助诊断指标。

Expression and significance of GABA transporter 2 antibody in patients with Crohn's disease

Objective　To investigate the expression of GABA transporter-2 (GAT-2) in intestinal tissue of patients with Crohn's disease (CD) and its relationship with clinicopathological features. Methods　Fifty-six patients with CD treated in the Affiliated Hospital of Yangzhou University from March 2010 to March 2021 were selected as an observation group, including 27 males and 29 females who were (32.30±9.40) years old; 68 cases of healthy physical examinees in the same period were selected as a control group, including 32 males and 36 females who were (34.76 ± 7.70) years old. Both groups were sent for pathological diagnosis after enteroscopy. The expressions of GAT-2 in intestinal mucosa of the CD patients and healthy examinees were measured by immunohistochemical staining and compared. The relationship between GAT-2 expression and inflammatory status in the patients with CD and its relationship with clinical case parameters were analyzed. SPSS 25.0 software was used for the statistical analysis. The measurement data of normal distribution were compared by t test, and the enumeration data by χ² test. Results　The positive expression rate of GAT-2 in intestinal mucosa of the observation gorup was significantly higher than that of the control group 83.93% (47/56) vs. 7.35% (5/68)], with a statistical difference (χ²=73.954, P<0.05). In the patients with CD, the expression score of GAT-2 in severe active phase was higher than those in moderate active phase, mild active phase, and remission phase respectively, with statistical differences (all P<0.05). There was a positive correlation between GAT-2 expression score and Crohn's disease activity index (CDAI) score (P<0.05). The positive rates of GAT-2 expressions in the CD patients with elevated CRP level, elevated ESR, and perianal lesions were significantly higher than those in the CD patients with normal CRP, normal ESR, and no perianal lesions (all P<0.05). Conclusion　GAT-2 is highly expressed in the intestinal mucosa of CD patients, mainly in the cytoplasm of interstitial lymphocytes, and its expression score is correlated with the clinical stage of CD, so it can be used as an auxiliary diagnostic indicator for clinical diagnosis.